Shots:

• The P-II (PAISLEY) study evaluating deucravacitinib (3/6mg, BID) vs PBO in 363 patients with mod. to sev. SLE
• The study met its 1EPs of achieving SRI(4) @32wk., a greater proportion of patients at 3 & 6mg, BID dose achieved SRI(4) (58.2% & 49.5% vs 34.4%) while 12mg, qd had numerically higher SRI(4) responses & responses were sustained across all groups ~48wk.
• The 2EPs showed clinical improvements @48wk, ≥50% reduction from baseline CLASI-50 & change in the active joint count, was well tolerated with the safety profile consistent with earlier trials with no evidence of laboratory abnormalities characteristic of JAK 1/2/3 inhibitorṣ. The company plans to advance the therapy in the P-III studies for SLE

Ref: BMS | Image: BMS